Meeting
2023 ASCO Annual Meeting
Head-to-head effectiveness and safety of pembrolizumab plus axitinib vs. nivolumab plus ipilimumab in metastatic renal cell carcinoma in the United States.
Authors
Dvir Aran
Faculty of Biology, Technion-Israel Institute of Technology, Haifa, Israel
Dvir Aran , Einat Granot-Hershkovitz , Shlomit Amar-Farkash , Keren Rosenberg-Katz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4532)
DOI
10.1200/JCO.2023.41.16_suppl.4532
Abstract #
4532
Poster Bd #
24
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Treatment patterns and costs among patients with metastatic renal cell carcinoma (mRCC) in the United States: A real-world study using integrated claims and clinical data.
First Author: Daniel M. Geynisman
Poster
2022 ASCO Annual Meeting
Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAFV600-mutant melanoma: Updated data from the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA.
First Author: Erika Richtig
Poster
2022 ASCO Genitourinary Cancers Symposium
Real-world clinical outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) in current immune-oncology (IO) and tyrosine kinase inhibitors (TKIs) era.
First Author: Neil J. Shah
Poster
2022 ASCO Genitourinary Cancers Symposium
Real-world assessment of changing treatment patterns and sequence for patients with metastatic renal cell carcinoma (mRCC) in the first-line (1L) setting.
First Author: Neil J. Shah